312 related articles for article (PubMed ID: 27405672)
1. Extended half-life clotting factor concentrates: results from published clinical trials.
Young G; Mahlangu JN
Haemophilia; 2016 Jul; 22 Suppl 5():25-30. PubMed ID: 27405672
[TBL] [Abstract][Full Text] [Related]
2. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
Collins P; Chalmers E; Chowdary P; Keeling D; Mathias M; O'Donnell J; Pasi KJ; Rangarajan S; Thomas A
Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
[TBL] [Abstract][Full Text] [Related]
3. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
Mahdi AJ; Obaji SG; Collins PW
Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia.
Morfini M; Farrugia A
Expert Rev Hematol; 2019 Oct; 12(10):883-892. PubMed ID: 31314609
[No Abstract] [Full Text] [Related]
5. Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.
von Mackensen S; Kalnins W; Krucker J; Weiss J; Miesbach W; Albisetti M; Pabinger I; Oldenburg J
Haemophilia; 2017 Jul; 23(4):566-574. PubMed ID: 28370896
[TBL] [Abstract][Full Text] [Related]
6. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
[TBL] [Abstract][Full Text] [Related]
7. Switching to extended half-life products in Canada - preliminary data.
Keepanasseril A; Stoffman J; Bouskill V; Carcao M; Iorio A; Jackson S;
Haemophilia; 2017 Jul; 23(4):e365-e367. PubMed ID: 28548284
[No Abstract] [Full Text] [Related]
8. Changing paradigm of prophylaxis with longer acting factor concentrates.
Carcao M
Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
Wang C; Young G
Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
[TBL] [Abstract][Full Text] [Related]
10. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
Brennan Y; Parikh S; McRae S; Tran H
Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
[TBL] [Abstract][Full Text] [Related]
11. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing.
Mancuso ME; Mahlangu JN; Pipe SW
Lancet; 2021 Feb; 397(10274):630-640. PubMed ID: 33460559
[TBL] [Abstract][Full Text] [Related]
12. The current status of prophylactic replacement therapy in children and adults with haemophilia.
Ljung R; Gretenkort Andersson N
Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
[TBL] [Abstract][Full Text] [Related]
13. Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.
Ducore JM; Miguelino MG; Powell JS
Expert Rev Hematol; 2014 Oct; 7(5):559-71. PubMed ID: 25142322
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
Négrier C; Abdul Karim F; Lepatan LM; Lienhart A; López-Fernández MF; Mahlangu J; Pabinger I; Li Y; Wolko D; Voigt C; Jacobs I; Santagostino E
Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
[TBL] [Abstract][Full Text] [Related]
15. Real-life experience in switching to new extended half-life products at European haemophilia centres.
Peyvandi F; Garagiola I; Boscarino M; Ryan A; Hermans C; Makris M
Haemophilia; 2019 Nov; 25(6):946-952. PubMed ID: 31418967
[TBL] [Abstract][Full Text] [Related]
16. Eftrenonacog Alfa: A Review in Haemophilia B.
Hoy SM
Drugs; 2017 Jul; 77(11):1235-1246. PubMed ID: 28646426
[TBL] [Abstract][Full Text] [Related]
17. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers.
Ivens IA; Baumann A; McDonald TA; Humphries TJ; Michaels LA; Mathew P
Haemophilia; 2013 Jan; 19(1):11-20. PubMed ID: 22913770
[TBL] [Abstract][Full Text] [Related]
18. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement.
Van den Bossche D; Peerlinck K; Jacquemin M
Int J Lab Hematol; 2018 May; 40 Suppl 1():21-29. PubMed ID: 29741261
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products.
Berntorp E; Andersson NG
Semin Thromb Hemost; 2016 Jul; 42(5):518-25. PubMed ID: 27096762
[TBL] [Abstract][Full Text] [Related]
20. Importance of pharmacokinetics in the management of hemophilia.
Barnes C
Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
